Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, Lingvay I, Senior PA, Silver RJ, Trevisan R, Rosenstock J. Bajaj HS, et al. Among authors: trevisan r. Diabetes Care. 2021 Jul;44(7):1586-1594. doi: 10.2337/dc20-2877. Epub 2021 Apr 19. Diabetes Care. 2021. PMID: 33875485 Free PMC article. Clinical Trial.
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.
Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, Ene-Iordache B, Ferrari S, Bossi AC, Trevisan R, Belviso A, Remuzzi G; Ezetimibe and Simvastatin in Dyslipidemia of Diabetes (ESD) Study Group. Ruggenenti P, et al. Among authors: trevisan r. Diabetes Care. 2010 Sep;33(9):1954-6. doi: 10.2337/dc10-0320. Epub 2010 Jun 21. Diabetes Care. 2010. PMID: 20566677 Free PMC article. Clinical Trial.
Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI).
Bruttomesso D, Bonomo M, Costa S, Dal Pos M, Di Cianni G, Pellicano F, Vitacolonna E, Dodesini AR, Tonutti L, Lapolla A, Di Benedetto A, Torlone E; Italian Group for Continuous Subcutaneous Insulin Infusion in Pregnancy. Bruttomesso D, et al. Diabetes Metab. 2011 Nov;37(5):426-31. doi: 10.1016/j.diabet.2011.02.002. Epub 2011 Apr 6. Diabetes Metab. 2011. PMID: 21474360
HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study.
Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events Study Group. Penno G, et al. Diabetes Care. 2013 Aug;36(8):2301-10. doi: 10.2337/dc12-2264. Epub 2013 Mar 14. Diabetes Care. 2013. PMID: 23491522 Free PMC article. Clinical Trial.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016. Parvanova A, et al. Among authors: trevisan r. Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. doi: 10.1016/S2213-8587(17)30359-5. Epub 2017 Nov 2. Lancet Diabetes Endocrinol. 2018. PMID: 29104158 Clinical Trial.
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Ruggenenti P, Trillini M, P Barlovic D, Cortinovis M, Pisani A, Parvanova A, Iliev IP, Ruggiero B, Rota S, Aparicio MC, Perna A, Peraro F, Diadei O, Gaspari F, Carrara F, Stucchi N, Martinetti D, Janez A, Gregoric N, Riccio E, Bossi AC, Trevisan R, Manunta P, Battaglia G, David S, Aucella F, Belviso A, Satta A, Remuzzi G; VALID Study Organization. Ruggenenti P, et al. Among authors: trevisan r. Diabetes Obes Metab. 2019 May;21(5):1177-1190. doi: 10.1111/dom.13639. Epub 2019 Feb 22. Diabetes Obes Metab. 2019. PMID: 30793466 Clinical Trial.
342 results